Group 1 - The stock of 加科思-B (01167) increased by over 5%, reaching an 8.61% rise to 11.23 HKD with a trading volume of 117 million HKD [1] - A report from The New York Times indicates that the Trump administration is considering an executive order to limit U.S. pharmaceutical companies from acquiring innovative drugs developed in China, which could disrupt the supply chain [1] - According to Shenwan Hongyuan's research report, the likelihood of this draft being implemented is very low, emphasizing the investment value of China's innovative drug sector supported by "innovation upgrade + profit inflection point + normalization of overseas business development" [1] Group 2 - 加科思 reported a mid-term revenue of 45.664 million RMB, compared to zero revenue in the same period last year [1] - The company recorded a loss attributable to owners of 58.994 million RMB, a year-on-year reduction of 65.1% [1] - The revenue growth is primarily attributed to milestone payments from the Elysium licensing agreement [1]

Market Overview - On May 30, the last trading day before the Dragon Boat Festival, the market opened lower and experienced weak fluctuations, with the North Stock 50 index rising by 0.25% while the Shanghai Composite Index fell by 0.31% to 3353.07 points [1] - The total trading volume of A-shares for the half day was 771.57 billion yuan [1] Monetary Policy - The People's Bank of China announced a 7-day reverse repurchase operation of 291.1 billion yuan at a fixed rate of 1.40%, with a net injection of 148.6 billion yuan for the day [1] Industry Developments - The China Securities Association is formulating a special evaluation method for securities companies, focusing on contributions to key areas such as technology finance, green finance, and digital finance [1] Pharmaceutical Sector Performance - The pharmaceutical sector saw significant gains, with stocks like Ruizhi Pharmaceutical and Huana Pharmaceutical hitting a 20% limit up, while other related sectors such as CRO and brain-computer interface also experienced upward trends [2] Sector Performance Data - The top performing sectors included: - Chicken: +2.55% - Innovative Drugs: +2.52% - Pork: +2.47% - Immune Therapy: +1.94% - COVID-19 Drug Concept: +1.94% [3] Investment Outlook for Innovative Drugs - The investment value of innovative drugs is viewed positively due to ongoing supportive policies, improving payment conditions, and upgrading research capabilities of supply-side enterprises [4] - Companies with strong innovation capabilities and rich product pipelines are expected to benefit in the long term from the continuous promotion of bulk purchasing of drugs and consumables [4] Company Profiles - **Huana Pharmaceutical**: A high-tech enterprise focused on the R&D, production, and sales of chemical drugs and traditional Chinese medicine, with a promising antidepressant drug ZG001 [7] - **Kexing Pharmaceutical**: An innovative biopharmaceutical company engaged in the R&D and sales of recombinant protein drugs and micro-ecological preparations, with a strong international presence [7] - **Guanhao Biological**: Actively advancing the application for a human genetic resource sample library to support innovation in drug development and health services [7] - **Haichuang Pharmaceutical**: An international innovative drug company focusing on cancer and metabolic diseases, utilizing PROTAC technology for drug development [8]